Literature DB >> 28182564

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Claus F Vogelmeier1,2, Gerard J Criner3,2, Fernando J Martinez4,2, Antonio Anzueto5, Peter J Barnes6, Jean Bourbeau7, Bartolome R Celli8, Rongchang Chen9, Marc Decramer10, Leonardo M Fabbri11, Peter Frith12, David M G Halpin13, M Victorina López Varela14, Masaharu Nishimura15, Nicolas Roche16, Roberto Rodriguez-Roisin17, Don D Sin18, Dave Singh19, Robert Stockley20, Jørgen Vestbo19, Jadwiga A Wedzicha6, Alvar Agusti21.   

Abstract

This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.
Copyright ©2017 the American Thoracic Society. Published with permission from the American Thoracic Society. Design and branding are copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28182564     DOI: 10.1183/13993003.00214-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  189 in total

Review 1.  Bronchoscopic lung volume reduction: recent updates.

Authors:  Anuradha Ramaswamy; Jonathan Puchalski
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 2.  Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.

Authors:  Arschang Valipour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Chitotriosidase Activity in Plasma and COPD Exacerbations.

Authors:  Matevz Harlander; David Lestan; Matjaz Turel
Journal:  Lung       Date:  2020-01-25       Impact factor: 2.584

4.  Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial.

Authors:  Thomas Keller; Laura J Spece; Lucas M Donovan; Edmunds Udris; Scott S Coggeshall; Matthew Griffith; Alexander D Bryant; Richard Casaburi; J Allen Cooper; Gerard J Criner; Philip T Diaz; Anne L Fuhlbrigge; Steven E Gay; Richard E Kanner; Fernando J Martinez; Ralph J Panos; David Shade; Alice Sternberg; Thomas Stibolt; James K Stoller; James Tonascia; Robert Wise; Roger D Yusen; David H Au; Laura C Feemster
Journal:  Chest       Date:  2020-04-09       Impact factor: 9.410

5.  Airways diseases: insights from the European Respiratory Society Annual Congress 2017.

Authors:  Alexander G Mathioudakis; Imran Satia; Ian M Adcock
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 6.  Anti-cytokines as a Strategy in Alpha-1 Antitrypsin Deficiency.

Authors:  Oisín F McElvaney; Mark P Murphy; Emer P Reeves; Noel G McElvaney
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

7.  COPD: A New Diagnostic Paradigm.

Authors:  Barry J Make
Journal:  Chronic Obstr Pulm Dis       Date:  2019-11

8.  A Formative Evaluation of Patient and Family Caregiver Perspectives on Early Palliative Care in Chronic Obstructive Pulmonary Disease across Disease Severity.

Authors:  Anand S Iyer; J Nicholas Dionne-Odom; Stephanie M Ford; Sheri L Crump Tims; Elizabeth D Sockwell; Nataliya V Ivankova; Cynthia J Brown; Rodney O Tucker; Mark T Dransfield; Marie A Bakitas
Journal:  Ann Am Thorac Soc       Date:  2019-08

9.  Inflammation and endothelial activation in early adulthood are associated with future emphysema: the CARDIA Lung Study.

Authors:  J Michael Wells; Laura A Colangelo; Lakshmi Sivarajan; Bharat Thyagarajan; Mark T Dransfield; Carlos Iribarren; Paul A Reyfman; David R Jacobs; George R Washko; Ravi Kalhan
Journal:  Eur Respir J       Date:  2019-01-17       Impact factor: 16.671

10.  Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung.

Authors:  Kristopher R Genschmer; Derek W Russell; Charitharth Lal; Tomasz Szul; Preston E Bratcher; Brett D Noerager; Mojtaba Abdul Roda; Xin Xu; Gabriel Rezonzew; Liliana Viera; Brian S Dobosh; Camilla Margaroli; Tarek H Abdalla; Robert W King; Carmel M McNicholas; J Michael Wells; Mark T Dransfield; Rabindra Tirouvanziam; Amit Gaggar; J Edwin Blalock
Journal:  Cell       Date:  2019-01-10       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.